Search Results - "Bascoul‐Mollevi, C."

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review by Charton, E., Cuer, B., Cottone, F., Efficace, F., Touraine, C., Hamidou, Z., Fiteni, F., Bonnetain, F., Woronoff-Lemsi, M.-C., Bascoul-Mollevi, C., Anota, A.

“…Purpose The time to deterioration (TTD) approach has been proposed as a modality of longitudinal analysis of patient-reported outcomes (PROs) in cancer…”
Get full text

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy by Lorch, Anja, Beyer, Jörg, Bascoul-Mollevi, Caroline, Kramar, Andrew, Einhorn, Lawrence H, Necchi, Andrea, Massard, Christophe, De Giorgi, Ugo, Fléchon, Aude, Margolin, Kim A, Lotz, Jean-Pierre, Germa Lluch, Jose Ramon, Powles, Thomas, Kollmannsberger, Christian K

“…To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure with cisplatin-based first-line chemotherapy. Data from…”
Get full text

Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD by Bascoul-Mollevi, C., Savina, Marion, Anota, Amélie, Barbieri, Antoine, Azria, David, Bonnetain, Franck, Gourgou, Sophie

“…•The first Stata command dedicated to the longitudinal analysis of HRQoL which allows performing the TTD and TUDD approaches.•A Stata command providing an…”
Get full text

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer by Bascoul-Mollevi, C., Gourgou, S., Galais, M.-P., Raoul, J.-L., Bouché, O., Douillard, J.-Y., Adenis, A., Etienne, P.-L., Juzyna, B., Bedenne, L., Conroy, T.

“…A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens…”
Get full text

TTD and %TUDD: New SAS macro programs to calculate the survival data of the time to deterioration for patient-reported outcomes data in oncology by Charton, E., Falcoz, A., François, E., Touraine, C., Bachet, J.-B., Louvet, C., Hamidou, Z., Bascoul-Mollevi, C., Anota, A.

“…•The new SAS macro programs, %TTD and %TUDD, calculate the time to deterioration.•Several definitions of deterioration were implemented following the recent…”
Get full text

Two-part statistics with paired data by Bascoul-Mollevi, C., Gourgou-Bourgade, S., Kramar, A.

“…In epidemiology, we often study data from a mixed distribution, i.e. with a clump of observations at zero and positive continuous data. Lachenbruch developed…”
Get full text

Quality of life and response shift effect of diffuse large B‐cell lymphoma French patients included in prospective real‐life REALYSA cohort in the first year after diagnosis by Anota, A., Basset, M., Belot, A., Bascoul‐Mollevi, C., Cottone, F., Efficace, F., Préau, M., Touraine, C., Damaj, G., Guidez, S., Labouré, G., Lionne‐Huyghe, P., Bonnet, A., Leyronnas, C., Guieze, R., Launay, V., Drenou, B., Fitoussi, O., Detourmignies, L., Soussain, C., Lachenal, F., Pica, G. M., Bernier, A., Charton, E., Ghesquieres, H.

Get full text

Early Stopping Rules in Clinical Trials Based on Sequential Monitoring of Serious Adverse Events by Kramar, A., Bascoul-Mollevi, C.

“…Several multistage or group sequential statistical methods have been developed for defining stopping rules in terms of efficacy in phase II and III clinical…”
Get full text

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts by Larbouret, C., Robert, B., Bascoul-Mollevi, C., Penault-Llorca, F., Ho-Pun-Cheung, A., Morisseau, S., Navarro-Teulon, I., Mach, J.-P., Pèlegrin, A., Azria, D.

“…Background: Pancreatic carcinoma remains a treatment-refractory cancer with a poor prognosis. Here, we compared anti-epidermal growth factor receptor (EGFR)…”
Get full text

A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer by Ho-Pun-Cheung, A, Assenat, E, Bascoul-Mollevi, C, Bibeau, F, Boissière-Michot, F, Thezenas, S, Cellier, D, Azria, D, Rouanet, P, Senesse, P, Ychou, M, Lopez-Crapez, E

“…Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response…”
Get full text

364 Prognostic Value of PI3KCA Mutations in 228 Consecutive Triple Negative Breast Cancers by Lamy, P.J, Mollevi-Bascoul, C, Laberenne, A.C, Bibeau, F, Senal, R, Romieu, G, Jacot, W

Get full text

SAE: An R package for early stopping rules in clinical trials by Bascoul-Mollevi, C, Laplanche, A, Le Deley, M.C, Kramar, A

“…Abstract In the case of an unexpected high frequency of serious adverse events (SAE), statistical methods are needed to help in the decision making process as…”
Get full text

202 POSTER Predicting a metastatic treatment response in advanced colorectal cancer patients by gene expression profiling by Del Rio, M, Bascoul-Mollevi, C, Bibeau, F, Chalbos, P, Kramar, A, Gongora, C, Ychou, M, Martineau, P

Get full text

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results: Qual Life Res by Bascoul-Mollevi, C., Barbieri, Antoine, Bourgier, C., Conroy, T., Chauffert, B., Hebbar, M., Jacot, W., Juzyna, B., de Forges, H., Gourgou, S., Bonnetain, F., Touraine, C., Anota, A.

“…PURPOSE: Health-related quality of life (HRQoL) is assessed by self-administered questionnaires throughout the care process. Classically, two longitudinal…”
Get full text

Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD: Comput Methods Programs Biomed by Bascoul-Mollevi, C., Savina, M., Anota, A., Barbieri, Antoine, Azria, D., Bonnetain, F., Gourgou, S.

“…BACKGROUND AND OBJECTIVE: Health-related quality of life (HRQoL) has become one relevant and available alternative endpoint of clinical trials in cancer…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Anota, A, Basset, M, Belot, A, Bascoul-Mollevi, C, Cottone, F, Efficace, F, Préau, M, Touraine, C, Damaj, G, Guidez, S, Labouré, G, Lionne-Huyghe, P, Bonnet, A, Leyronnas, C, Guieze, R, Launay, V, Drenou, B, Fitoussi, O, Detourmignies, L, Soussain, C, Lachenal, F, Pica, G M, Bernier, A, Charton, E, Ghesquieres, H

Get full text

In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption by Larbouret, Christel, Gaborit, Nadège, Chardès, Thierry, Coelho, Mickaël, Campigna, Emmanuelle, Bascoul-Mollevi, Caroline, Mach, Jean-Pierre, Azria, David, Robert, Bruno, Pèlegrin, André

“…Abstract We previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epidermal growth factor receptor [EGFR] monoclonal antibody,…”
Get full text

Item Response Theory and Factor Analysis as Mean to Characterize Occurrence of Response Shift for Longitudinal Quality of Life Study in Breast Cancer Patients by Anota, A., Bascoul-Mollevi, C., Guillemin, F., Conroy, T., Velten, M., Jolly, D., Mercier, M., Causeret, S., Dabakuyo, T.S., Bonnetain, F.

Get full text

Two-part statistics with paired data: TWO-PART STATISTICS by Bascoul-Mollevi, C., Gourgou-Bourgade, S., Kramar, A.

Get full text

R109: Vaccination à l’aide de scFv humains anti-trastuzumab : réversion de la tolérance immunologique vis-à-vis de HER2 et induction d’une immunité antitumorale dans les souris MMTV. f.huHER2(Fo5) by Ladjemi Maha, Z., Chardès, T., Corgnac, S., Garambois, V., Morisseau, S., Robert, B., Bascoul-Mollevi, C., Aït Arsa, I., Jacot, W., Pouget, J.P., Pèlegrin, A., Navarro-Teulon, I.

Get full text